It depends on which polio vaccine you’re talking about. There are two types: the oral polio vaccine (OPV) contains a live, weakened virus, while the injectable polio vaccine (IPV) contains a killed virus. If you live in the United States, your child receives only the inactivated (killed) version, and has since the year 2000. Many other countries, particularly in Africa and South Asia, still use the live oral version.
Two Vaccines, Two Different Approaches
The oral polio vaccine, developed by Albert Sabin, uses a live virus that has been weakened so it can no longer cause disease in healthy people. You swallow it as drops. Once inside, the weakened virus replicates in your gut, triggering a strong immune response both in the intestines and throughout the body. That gut-level immunity is what makes OPV uniquely effective at stopping transmission: vaccinated people shed much less virus if they’re later exposed to wild polio.
The inactivated polio vaccine, given as a shot, contains poliovirus that has been completely killed. It cannot replicate at all. IPV produces strong antibodies in the bloodstream, which protect against paralysis very effectively, but it does comparatively little to stop the virus from replicating in the intestines. That means someone vaccinated only with IPV could still carry and spread poliovirus without getting sick themselves.
Why the U.S. Stopped Using the Live Vaccine
Wild polio was eliminated from the United States in 1979. Throughout the 1980s and 1990s, the only cases of paralytic polio in the country were caused by the vaccine itself. In very rare instances, the weakened live virus in OPV can mutate back toward a form capable of causing paralysis. The risk is small, roughly 1 case per 2.9 million doses administered, but once wild polio was gone, even that tiny risk was no longer justifiable.
So in 2000, the U.S. switched entirely to IPV. Children now receive four doses of the inactivated vaccine at 2 months, 4 months, 6 through 18 months, and 4 through 6 years. The shot is given either on its own or bundled into combination vaccines that also cover diseases like diphtheria, tetanus, and whooping cough. There is zero risk of vaccine-caused polio from IPV because the virus in it is dead.
Where the Live Vaccine Is Still Used
OPV remains a critical tool in countries where polio still circulates or where the risk of outbreaks is high. Afghanistan, Nigeria, India, Egypt, Bangladesh, Angola, and many other nations include OPV in their routine childhood vaccination schedules. Several practical reasons explain why. OPV is cheaper to produce and easier to administer (no needles, no trained injectors needed). Its ability to trigger intestinal immunity helps interrupt transmission in communities, and the weakened virus shed by vaccinated children can passively immunize others nearby.
Most high-income countries, including Australia, the U.K., and all of western Europe, have switched exclusively to IPV, following the same logic as the United States. Canada, Japan, and others made similar transitions once wild polio was no longer a domestic threat.
The Risk of Vaccine-Derived Polio
The live vaccine’s biggest drawback is that the weakened virus can, over time, evolve back into a dangerous form. When a child receives OPV, the vaccine virus replicates in the gut and is excreted for a limited time. In well-vaccinated communities, this isn’t a problem. But in areas with low vaccination rates and poor sanitation, the excreted virus can circulate from person to person for months. Over 12 to 18 months of uninterrupted transmission, genetic changes can accumulate until the virus regains the ability to cause paralysis. This is called circulating vaccine-derived poliovirus (cVDPV).
These outbreaks are rare but real. They tend to occur in exactly the places least equipped to handle them: communities with crowded conditions, inadequate sanitation, and gaps in immunization coverage. The virus can also recombine with related viruses in the gut, further increasing its ability to spread and cause disease.
A Newer, More Stable Live Vaccine
To address this problem, researchers developed a modified version of the oral vaccine called nOPV2 (novel oral polio vaccine type 2). It still contains a live, weakened virus and still works the same way, replicating in the gut and triggering intestinal immunity. The key difference is that its genetic code has been engineered to be more stable, making it significantly less likely to revert to a form that can cause paralysis. nOPV2 provides comparable protection to the older oral vaccine while reducing the risk of seeding new vaccine-derived outbreaks. It is now being used in outbreak response campaigns in multiple countries.
What This Means for You
If you or your child are being vaccinated in the United States, the polio vaccine you receive is not live. It is the inactivated, injectable form, and it carries no risk of causing polio. It is highly effective at preventing paralytic disease.
If you’re traveling to a country that uses OPV, or if your child was vaccinated abroad with oral drops, that was the live vaccine. For the vast majority of recipients it’s safe and effective, with the added benefit of strong intestinal immunity. The risk of vaccine-associated paralysis from OPV, while real, is on the order of 1 case per several million doses. For countries still fighting active polio transmission, that tradeoff remains worthwhile, especially as the newer, more genetically stable oral vaccines become widely available.